Free Trial
→ “This Changes Everything” - Trump Hands Millions Massive IRS Gift (From Colonial Metals) (Ad) Free ARDT Stock Alerts

Ardent Health Partners (ARDT) Stock Forecast & Price Target

Ardent Health Partners logo
$16.45 -0.19 (-1.14%)
(As of 11/20/2024 ET)
Compare

Ardent Health Partners - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 12 Analyst Ratings
Sell
0
Hold
2
Buy
10

Based on 12 Wall Street analysts who have issued ratings for Ardent Health Partners in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 2 have given a hold rating, 8 have given a buy rating, and 2 have given a strong buy rating for ARDT.

Consensus Price Target

$21.82
32.63% Upside
According to the 12 analysts' twelve-month price targets for Ardent Health Partners, the average price target is $21.82. The highest price target for ARDT is $27.00, while the lowest price target for ARDT is $18.00. The average price target represents a forecasted upside of 32.63% from the current price of $16.45.
Get the Latest News and Ratings for ARDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ardent Health Partners and its competitors.

Sign Up

ARDT Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24		1 Month Ago
10/23/23 to 10/22/24		3 Months Ago
8/24/23 to 8/23/24		1 Year Ago
11/22/22 to 11/22/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
 N/A
Buy
8 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
 N/A
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price Target$21.82$21.91$21.70N/A
Forecasted Upside32.63% Upside13.28% Upside25.65% UpsideN/A
Consensus Rating
Buy
Buy
Buy
N/A

ARDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ardent Health Partners Stock vs. The Competition

TypeArdent Health PartnersMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside32.63% Upside26,931.56% Upside9.82% Upside
News Sentiment Rating
Positive News

See Recent ARDT News
Neutral News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/14/2024Royal Bank of Canada
4 of 5 stars		B. Hendrix
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOutperform ➝ Outperform$23.00 ➝ $23.00+28.56%
11/12/2024Leerink Partners
1 of 5 stars		 Boost TargetOutperform ➝ Outperform$23.00 ➝ $25.00+44.43%
11/6/2024Bank of America
4 of 5 stars		 DowngradeBuy ➝ Neutral$22.00 ➝ $19.00+5.15%
10/11/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$24.00+32.45%
9/19/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Fidel
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Overweight$24.00 ➝ $24.00+37.14%
8/12/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeStrong-Buy
8/12/2024Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		T. Greaves
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy ➝ Buy$18.00 ➝ $18.00+15.09%
8/12/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Cassorla
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy$21.00+34.27%
8/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$27.00+72.63%
8/12/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageNeutral$18.00+15.09%
8/12/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOutperform$20.00+27.88%
8/12/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy ➝ Buy$21.00 ➝ $21.00+34.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:02 AM ET.


ARDT Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Ardent Health Partners is $21.82, with a high forecast of $27.00 and a low forecast of $18.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardent Health Partners in the last twelve months. There are currently 2 hold ratings, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDT shares.

According to analysts, Ardent Health Partners's stock has a predicted upside of 32.63% based on their 12-month stock forecasts.

Over the previous 90 days, Ardent Health Partners's stock had 1 upgrade and 1 downgrade by analysts.

Ardent Health Partners has been rated by research analysts at Bank of America, KeyCorp, Leerink Partners, Royal Bank of Canada, and Stephens in the past 90 days.

Analysts like Ardent Health Partners more than other "medical" companies. The consensus rating for Ardent Health Partners is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARDT compares to other companies.

Related Companies
Today's Ratings
Top Rated Stocks
More Ratings Tools

This page (NYSE:ARDT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners
Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time N...
Behind the Markets | Sponsored